These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

191 related items for PubMed ID: 27593862

  • 21. Immunogenicity and safety of an AS03-adjuvanted H5N1 pandemic influenza vaccine in Korean adults: a phase IV, randomized, open-label, controlled study.
    Izurieta P, Kim WJ, Wie SH, Lee J, Lee JS, Dramé M, Vaughn DW, Schuind A.
    Vaccine; 2015 Jun 04; 33(24):2800-7. PubMed ID: 25910919
    [Abstract] [Full Text] [Related]

  • 22. Safety and Immunogenicity of an Egg-Cultivated Quadrivalent Inactivated Split-virion Influenza Vaccine (GC3110A) in Healthy Korean Children: a Randomized, Double-blinded, Active-controlled Phase III Study.
    Lee J, Lee KY, Kim JH, Kim CS, Eun BW, Kim HM, Kim DH, Hong YJ, Choi YY, Jo DS, Ma SH, Kang JH.
    J Korean Med Sci; 2018 Mar 26; 33(13):e100. PubMed ID: 29573247
    [Abstract] [Full Text] [Related]

  • 23. A phase 2/3 double-blind, randomized, placebo-controlled study to evaluate the safety and immunogenicity of a seasonal trivalent inactivated split-virion influenza vaccine (IVACFLU-S) in healthy adults in Vietnam.
    Lan PT, Toan NT, Thang HA, Thang TC, Be LV, Thai DH, Huong VM, Nga NT, Tang Y, Holt R, Francesco BS, Flores J, Tewari T.
    Hum Vaccin Immunother; 2019 Mar 26; 15(12):2933-2939. PubMed ID: 31070986
    [Abstract] [Full Text] [Related]

  • 24. Immunogenicity and sustainability of the immune response in Brazilian HIV-1-infected individuals vaccinated with inactivated triple influenza vaccine.
    Souza TM, Santini-Oliveira M, Martorelli A, Luz PM, Vasconcellos MT, Giacoia-Gripp CB, Morgado M, Nunes EP, Lemos AS, Ferreira AC, Moreira RI, Veloso VG, Siqueira M, Grinsztejn B, Camacho LA.
    J Med Virol; 2016 Mar 26; 88(3):426-36. PubMed ID: 26267817
    [Abstract] [Full Text] [Related]

  • 25. Safety, tolerability, and immunogenicity of inactivated trivalent seasonal influenza vaccine administered with a needle-free disposable-syringe jet injector.
    Simon JK, Carter M, Pasetti MF, Sztein MB, Kotloff KL, Weniger BG, Campbell JD, Levine MM.
    Vaccine; 2011 Nov 28; 29(51):9544-50. PubMed ID: 21986218
    [Abstract] [Full Text] [Related]

  • 26. Safety and immunogenicity of an AS03-adjuvanted A(H1N1)pmd09 vaccine administered simultaneously or sequentially with a seasonal trivalent vaccine in adults 61 years or older: data from two multicentre randomised trials.
    Peeters M, Regner S, Vaman T, Devaster JM, Rombo L.
    Vaccine; 2012 Oct 05; 30(45):6483-91. PubMed ID: 22885014
    [Abstract] [Full Text] [Related]

  • 27. Immunogenicity and safety of a cell culture-derived inactivated quadrivalent influenza vaccine (NBP607-QIV): A randomized, double-blind, multi-center, phase III clinical trial in adults and elderly subjects.
    Choi WS, Noh JY, Song JY, Cheong HJ, Wie SH, Lee JS, Lee J, Kim SW, Jeong HW, Jung SI, Kim YS, Woo HJ, Kim KH, Kim H, Kim WJ.
    Hum Vaccin Immunother; 2017 Jul 03; 13(7):1653-1660. PubMed ID: 28406746
    [Abstract] [Full Text] [Related]

  • 28. Safety and immunogenicity of a quadrivalent inactivated influenza vaccine compared to licensed trivalent inactivated influenza vaccines in adults.
    Greenberg DP, Robertson CA, Noss MJ, Blatter MM, Biedenbender R, Decker MD.
    Vaccine; 2013 Jan 21; 31(5):770-6. PubMed ID: 23228813
    [Abstract] [Full Text] [Related]

  • 29. Immunogenicity and safety of the first indigenously developed Indian tetravalent influenza vaccine (split virion) in healthy adults ≥ 18 years of age: A randomized, multicenter, phase II / III clinical trial.
    Sharma S, Singh VB, Kumar S, Prajapati V, Patel J, Vukkala R, Jangid SK, Sanmukhani J, Gupta G, Patel P, Mittal R, Glueck R.
    Hum Vaccin Immunother; 2018 Jun 03; 14(6):1362-1369. PubMed ID: 29461913
    [Abstract] [Full Text] [Related]

  • 30. Active-controlled phase III study of an egg-cultivated quadrivalent inactivated split-virion influenza vaccine (GC3110A) in healthy Korean children aged 6-35 months.
    Choi UY, Kim KH, Lee KY, Kim JH, Kim CS, Eun BW, Kim HM, Kim DH, Song SE, Jo DS, Lee J, Ma SH, Kim KN, Kang JH.
    Vaccine; 2021 Apr 08; 39(15):2103-2109. PubMed ID: 33736920
    [Abstract] [Full Text] [Related]

  • 31. Comparison of immunogenicity and reactogenicity of split versus subunit influenza vaccine in Korean children aged 6-35 months.
    Kim YK, Eun BW, Kim NH, Kang EK, Lee BS, Kim DH, Lim JS.
    Scand J Infect Dis; 2013 Jun 08; 45(6):460-8. PubMed ID: 23294036
    [Abstract] [Full Text] [Related]

  • 32. A Phase III randomised trial of the immunogenicity and safety of quadrivalent versus trivalent inactivated subunit influenza vaccine in adult and elderly subjects, assessing both anti-haemagglutinin and virus neutralisation antibody responses.
    van de Witte S, Nauta J, Montomoli E, Weckx J.
    Vaccine; 2018 Sep 25; 36(40):6030-6038. PubMed ID: 29709447
    [Abstract] [Full Text] [Related]

  • 33. Immunogenicity and safety of a quadrivalent inactivated influenza vaccine in children 6-59 months of age: A phase 3, randomized, noninferiority study.
    Statler VA, Albano FR, Airey J, Sawlwin DC, Graves Jones A, Matassa V, Heijnen E, Edelman J, Marshall GS.
    Vaccine; 2019 Jan 07; 37(2):343-351. PubMed ID: 30057283
    [Abstract] [Full Text] [Related]

  • 34. A reduced-dose seasonal trivalent influenza vaccine is safe and immunogenic in adult and elderly patients in a randomized controlled trial.
    Vajo Z, Tamas F, Jankovics I.
    Clin Vaccine Immunol; 2012 Mar 07; 19(3):313-8. PubMed ID: 22219315
    [Abstract] [Full Text] [Related]

  • 35. Safety and immunogenicity of trivalent inactivated influenza vaccine in infants.
    Halasa NB, Gerber MA, Chen Q, Wright PF, Edwards KM.
    J Infect Dis; 2008 May 15; 197(10):1448-54. PubMed ID: 18444800
    [Abstract] [Full Text] [Related]

  • 36. Safety and immunogenicity of high-dose trivalent inactivated influenza vaccine in adults 50-64 years of age.
    DiazGranados CA, Saway W, Gouaux J, Baron M, Baker J, Denis M, Jordanov E, Landolfi V, Yau E.
    Vaccine; 2015 Dec 16; 33(51):7188-7193. PubMed ID: 26555348
    [Abstract] [Full Text] [Related]

  • 37. Immunogenicity and safety of Intanza(®)/IDflu(®) intradermal influenza vaccine in South Korean adults: a multicenter, randomized trial.
    Hoon Han S, Hee Woo J, Weber F, Joo Kim W, Ran Peck K, Il Kim S, Hwa Choi Y, Myung Kim J.
    Hum Vaccin Immunother; 2013 Sep 16; 9(9):1971-7. PubMed ID: 23778938
    [Abstract] [Full Text] [Related]

  • 38. Immunogenicity and safety of three 2010-2011 seasonal trivalent influenza vaccines in Chinese toddlers, children and older adults: a double-blind and randomized trial.
    Luo FJ, Yang LQ, Ai X, Bai YH, Wu J, Li SM, Zhang Z, Lu M, Li L, Wang ZY, Shi NM.
    Hum Vaccin Immunother; 2013 Aug 16; 9(8):1725-34. PubMed ID: 23896581
    [Abstract] [Full Text] [Related]

  • 39. Safety and immunogenicity of a quadrivalent inactivated influenza vaccine in adults.
    Pépin S, Donazzolo Y, Jambrecina A, Salamand C, Saville M.
    Vaccine; 2013 Nov 12; 31(47):5572-8. PubMed ID: 24016810
    [Abstract] [Full Text] [Related]

  • 40. Phase 4 randomized trial of intradermal low-antigen-content inactivated influenza vaccine versus standard-dose intramuscular vaccine in HIV-1-infected adults.
    Ansaldi F, Valle L, de Florentiis D, Parodi V, Murdaca G, Bruzzone B, Durando P, Setti M, Icardi G.
    Hum Vaccin Immunother; 2012 Aug 12; 8(8):1048-52. PubMed ID: 22832261
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 10.